GLARITUS (Insulin Glargine (100IU/ml))

Glaritus Injection is a long-acting insulin formulation designed to manage blood glucose levels in individuals with type 1 and type 2 diabetes, applicable to both adults and pediatric populations. This medication delivers a consistent supply of insulin throughout the day, aiding in the regulation of blood sugar levels and minimizing potential diabetes-related complications. Glaritus can be utilized as a standalone therapy or in conjunction with rapid-acting insulins or other antidiabetic agents as determined by a healthcare professional. Proper administration techniques for subcutaneous injection will be provided by your healthcare provider. Adhering to the prescribed dosage is crucial for optimal therapeutic outcomes; discontinuing use may lead to significantly elevated blood sugar levels, thereby increasing the risk of severe health issues. The management of diabetes should also encompass a balanced diet, consistent exercise regime, and, where necessary, weight management, all under your physician’s guidance. Hypoglycemia, or low blood sugar, is the most frequently reported adverse effect associated with Glaritus Injection. To mitigate this risk, it is essential to administer the correct dosage, maintain regular meal patterns, and routinely monitor blood glucose levels. Additionally, excessive alcohol intake can precipitate hypoglycemia. Other potential side effects include localized swelling, adverse skin reactions, lipid distribution changes at injection sites, rashes, itching, and weight increase.